BIOMODEX: Results of First Clinical Study Using Patient-Specific Brain Aneurysm Models for Pre-Procedural Rehearsals

July 1, 2020

BIOMODEX announced the results of the first clinical study using the BIOMODEX® EVIAS™ 3D printed models to plan aneurysm treatment using endovascular robotics and novel flow diverter devices.

The findings, which were published in the Journal of NeuroInterventional Surgery (JNIS) this month, demonstrate how use of the 3D printed aneurysm models for pre-procedural rehearsal allows physicians to rehearse for procedures more accurately and reliably.

The first-of-its kind study involved 8 patients with brain aneurysms who were scheduled for treatment using new devices or techniques. Two cases included simulation of stent-assisted coiling treatments using the assistance of a robotic arm by Corindus, a Siemens Healthineers Company, and six included rehearsal for first time use of new-generation flow-diverter stents, including the Silk Vista Baby by Balt and SurpassEvolve by Stryker. All rehearsals and procedures were performed by Dr. Vitor Mendes Pereira, a neurosurgeon and neuroradiologist at Toronto Western Hospital in Canada.

“This technology has the potential to increase operator confidence and improve patient outcomes, particularly in first in-human experiences using new devices and robotics. The rehearsals were instrumental in our recent successful completion of the world’s first in-human robotic-assisted neurovascular intervention,” said Dr. Pereira, senior author of the study and lead scientist of the RADIS lab research team (@RADIS_lab).

Biomodex’s 3D training models were created based on each patient’s unique CTA scans and printed using a Stratasys J750 Digital Anatomy 3D Printer. Biomodex® Invivotech® material was used to simulate the biomechanics of the aneurysm and the surrounding tissue. The models are made with various flexible photopolymers which, unlike single material models like silicone, allow control of the pliability of the target area, providing critical tactile feedback. The models are connected to the EVIAS station which includes a hydraulic system to replicate blood flow. The research study, led by RADIS lab’s clinical research technologist, Nicole Cancelliere, found the models to be a reliable and accurate reproduction of the aneurysm features and the parent vessel anatomy.

“The rehearsals allowed the operator to address issues, such as device sizing, and practice challenging maneuvers, such as how to open flow diverter stents,” said Cancelliere, lead co-author of the study. The study demonstrated how various procedural challenges were successfully replicated during the patient’s treatment.

“These early results are encouraging and reconfirms initial anecdotal evidence,” said BIOMODEX® CEO Ziad Rouag. “We are privileged to work hand-in-hand with key opinion leaders like Dr. Pereira and his team at Toronto Western Hospital to further develop our vision of establishing Biomodex as the standard-of-care in patient-specific rehearsals. We look forward to announcing positive results on additional studies we have planned for our various other applications.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”